Clinical Trial

Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma

Study acronym: RADICAL
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The addition of targeted immunotherapy will be safe and well tolerated and facilitate the reduction of anthracycline exposure while preserving lymphoma disease control in children, adolescents and young adults (CAYA) with mature B-cell non-Hodgkin lymphoma (MB-NHL) and classical Hodgkin lymphoma (cHL).
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2022-02-22; most recent amendment 2025-06-10.
Trial Details
NCT Number NCT05253495
Lead Sponsor New York Medical College
Conditions Non-hodgkin Lymphoma, Hodgkin Lymphoma
Enrollment 80 participants
Start Date 2022-02-01
Primary Completion 2027-12-31 (estimated)
Study Completion 2028-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-06-13